UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 111

Sortiert nach

Revised UK guidelines for the management of cutaneous melanoma 2010

Journal of plastic, reconstructive & aesthetic surgery, 2010-09, Vol.63 (9), p.1401-1419

2010

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC)

Gynecologic oncology, 2012-04, Vol.125 (1), p.31-36

2012

Link zum Volltext

Verfügbarkeit prüfen

Assessing the impact of evolving evidence in renal cell carcinoma treatment: An update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT)

European journal of cancer (1990), 2014-12, Vol.50 (18), p.3153-3160

2014

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of treatment options for patients with advanced renal cell carcinoma: Assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology

European journal of cancer (1990), 2012-05, Vol.48 (7), p.1038-1047

2012

Link zum Volltext

Verfügbarkeit prüfen

Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer

European journal of obstetrics & gynecology and reproductive biology, 2008-05, Vol.138 (1), p.71-75

2008

Link zum Volltext

Verfügbarkeit prüfen

The role of human endogenous retroviruses in melanoma

British journal of dermatology (1951), 2009-12, Vol.161 (6), p.1225-1231

2009

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review

Clinical oncology (Royal College of Radiologists (Great Britain)), 2012-08, Vol.24 (6), p.410-412

2012

Link zum Volltext

Verfügbarkeit prüfen

Primary Excision Margins and Sentinel Lymph Node Biopsy in Clinically Node-negative Melanoma of the Trunk or Extremities

Clinical oncology (Royal College of Radiologists (Great Britain)), 2011-11, Vol.23 (9), p.569-571

2011

Link zum Volltext

Verfügbarkeit prüfen

1006 ORAL Prognostic Factors for Progression-free Survival (PFS), Overall Survival (OS), and Long-term OS (LT-OS) With Sunitinib in 1,059 Patients, Treated on Clinical Trials, With Metastatic Renal Cell Carcinoma (mRCC)

European journal of cancer (1990), 2011, Vol.47, p.S98-S99

2011

Link zum Volltext

Verfügbarkeit prüfen

Epirubicin, Cisplatin and Protracted Venous Infusion 5-Fluorouracil Chemotherapy for Advanced Salivary Adenoid Cystic Carcinoma

Clinical oncology (Royal College of Radiologists (Great Britain)), 2009-05, Vol.21 (4), p.311-314

2009

Link zum Volltext

Verfügbarkeit prüfen

A feasibility study of sequential doublet chemotherapy comprising carboplatin–doxorubicin and carboplatin–paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma

Annals of oncology, 2009-11, Vol.20 (11), p.1787-1793

2009

Link zum Volltext

Verfügbarkeit prüfen

Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities

British journal of dermatology (1951), 2012-11, Vol.167 (5), p.987-994

2012

Link zum Volltext

Verfügbarkeit prüfen

Pathogenesis, clinical evolution and outcomes of patients with immune checkpoint inhibitor induced acute liver injury: A multicentre study

Annals of oncology, 2018-10, Vol.29, p.viii430-viii430

2018

Link zum Volltext

Verfügbarkeit prüfen

MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii147

2018

Link zum Volltext

Verfügbarkeit prüfen

Ovarian Carcinosarcoma Management: a Retrospective Analysis of the Royal Marsden Experience

Annals of oncology, 2014-09, Vol.25, p.iv314

2014

Link zum Volltext

Verfügbarkeit prüfen

Implementation of Routine Brca Gene Testing of Ovarian Cancer (Oc) Patients at Royal Marsden Hospital

Annals of oncology, 2014-09, Vol.25, p.iv307

2014

Link zum Volltext

Verfügbarkeit prüfen

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Gynecologic oncology, 2018-06, Vol.149, p.246-247

2018

Link zum Volltext

Verfügbarkeit prüfen

The significance of paracardiac lymph node enlargement in ovarian cancer

Clinical radiology, 1997-09, Vol.52 (9), p.692-697

1997

Link zum Volltext

Verfügbarkeit prüfen

Mucinous ovarian cancer

International journal of gynecological cancer, 2008-03, Vol.18 (2), p.209-214

2008

Link zum Volltext

Verfügbarkeit prüfen

Vegetative Compatibility and Pathogenicity of Verticillium dahliae Isolates from the Aegean Region of Turkey

Phytoparasitica, 2007, Vol.35 (3), p.222-231

Gore, M.E

2007

Link zum Volltext

Verfügbarkeit prüfen

49LBA Final results of a Phase II randomised study of cediranib (RECENTIN™) in patients with advanced renal cell carcinoma (RCC)

European journal of cancer supplements, 2009, Vol.7 (3), p.21-21

2009

Link zum Volltext

Verfügbarkeit prüfen

Second primary melanomas on treatment with vemurafenib: reply from the authors: Correspondence

British journal of dermatology (1951), 2013-04, Vol.168 (4), p.888-889

2013

Link zum Volltext

Verfügbarkeit prüfen

972PD - Efficacy of Platinum Plus Gemcitabine (G) in Platinum-Resistant (R) Compared to Platinum-Sensitive (S) Ovarian Cancer: the Royal Marsden Experience

Annals of oncology, 2012-09, Vol.23, p.ix320-ix320

2012

Link zum Volltext

Verfügbarkeit prüfen

Interim Results of a Phase II Study of Sunitinib and Low Dose Metronomic Cyclophosphamide in Advanced Renal Cell Cancer

Annals of oncology, 2012-09, Vol.23, p.ix273-ix274

2012

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Platinum Plus Gemcitabine (G) in Platinum-Resistant (R) Compared to Platinum-Sensitive (S) Ovarian Cancer: the Royal Marsden Experience

Annals of oncology, 2012-09, Vol.23, p.ix320

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 111

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(103)
Mit Volltextzugriff
(107)

Publikationsform

Artikel
(110)
Dissertationen
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(69)
Life Sciences & Biomedicine
(67)
Humans
(62)
Biological And Medical Sciences
(46)
Medical Sciences
(45)
Female
(43)
Oncology
(37)
Adult
(34)
Middle Aged
(31)
Aged
(25)
Male
(21)
Pharmacology. Drug Treatments
(21)
Antineoplastic Agents
(18)
Chemotherapy
(18)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(16)
Tumors
(16)
Dermatology
(13)
Ovarian Neoplasms - Drug Therapy
(11)
Treatment Outcome
(11)
Tumors Of The Skin And Soft Tissue. Premalignant Lesions
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Revised UK guidelines for the management of cutaneous melanoma 2010

Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC)

Assessing the impact of evolving evidence in renal cell carcinoma treatment: An update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT)

Evaluation of treatment options for patients with advanced renal cell carcinoma: Assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology

Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer

The role of human endogenous retroviruses in melanoma

Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review

Primary Excision Margins and Sentinel Lymph Node Biopsy in Clinically Node-negative Melanoma of the Trunk or Extremities

1006 ORAL Prognostic Factors for Progression-free Survival (PFS), Overall Survival (OS), and Long-term OS (LT-OS) With Sunitinib in 1,059 Patients, Treated on Clinical Trials, With Metastatic Renal Cell Carcinoma (mRCC)

Epirubicin, Cisplatin and Protracted Venous Infusion 5-Fluorouracil Chemotherapy for Advanced Salivary Adenoid Cystic Carcinoma

A feasibility study of sequential doublet chemotherapy comprising carboplatin–doxorubicin and carboplatin–paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma

Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities

Pathogenesis, clinical evolution and outcomes of patients with immune checkpoint inhibitor induced acute liver injury: A multicentre study

MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

Ovarian Carcinosarcoma Management: a Retrospective Analysis of the Royal Marsden Experience

Implementation of Routine Brca Gene Testing of Ovarian Cancer (Oc) Patients at Royal Marsden Hospital

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

The significance of paracardiac lymph node enlargement in ovarian cancer

Mucinous ovarian cancer

Vegetative Compatibility and Pathogenicity of Verticillium dahliae Isolates from the Aegean Region of Turkey

49LBA Final results of a Phase II randomised study of cediranib (RECENTIN™) in patients with advanced renal cell carcinoma (RCC)

Second primary melanomas on treatment with vemurafenib: reply from the authors: Correspondence

972PD - Efficacy of Platinum Plus Gemcitabine (G) in Platinum-Resistant (R) Compared to Platinum-Sensitive (S) Ovarian Cancer: the Royal Marsden Experience

Interim Results of a Phase II Study of Sunitinib and Low Dose Metronomic Cyclophosphamide in Advanced Renal Cell Cancer

Efficacy of Platinum Plus Gemcitabine (G) in Platinum-Resistant (R) Compared to Platinum-Sensitive (S) Ovarian Cancer: the Royal Marsden Experience

Suchergebnisse filtern